Abstract
Background: Due to anti-SARS-CoV-2 antibody decay and SARS-CoV-2 variants, vaccine booster doses are a constant concern. It was focused on whether the third dose can quickly evoke and activate immunity and produce a sufficient and durable immune protection.
Objectives: To evaluate the responses and durations of five subsets of anti-SARS-CoV-2 antibodies and their predictive values for protection after the administration of a three-dose inactivated SARS-CoV-2 vaccines regimens.
Methods: A prospective cohort study of five subsets of anti-SARS-CoV-2 antibodies (neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA) was carried out to evaluate the efficacies and immune characteristics of a three-dose inactivated SARS-CoV-2 vaccines regimen in 32 volunteers. The dynamic response and immune decay were longitudinally profiled at 18 serial time points over 368 days.
Results: The neutralizing antibody, anti-RBD total antibody, anti-Spike IgG and anti-Spike IgA levels rapidly increased to 773.60 (380.90-1273.00) IU/mL, 639.30 (399.60-878.60) AU/mL, 34.48 (16.83-44.68) S/CO and 0.91 (0.35-1.14) S/CO, respectively, after the administration of the third dose. Compared to the peak value after the second dose, these values were increased by 4.22-fold, 3.71-fold, 1.01-fold and 0.92-fold. On the other hand, the half-lives of the neutralizing antibody, anti-RBD total antibody, and anti-Spike IgG were 56.26 (95% CI, 46.81 to 70.49) days, 66.37 (95% CI, 54.90 to 83.88) days, and 82.91 (95% CI, 63.65 to 118.89) days, respectively. Compared to the half-lives after the second dose, these values were increased by 1.71-fold, 2.00-fold, and 2.93-fold, respectively. Nevertheless, the positive conversion rate of anti-Spike IgM was decreased to 9.38% (3/32), which was much lower than that after the second dose (65.63% (21/32)).
Conclusions: Compared to the second dose, the third dose dramatically increased the antibody levels and decay times. However, the half-life of neutralizing antibody remained unsatisfactory. Due to decay, a fourth dose, and even annual revaccination, might be considered in the SARS-CoV-2 vaccination management strategy.
Keywords: COVID-19; CoronaVac; SARS-CoV-2; anti-SARS-CoV-2 antibody; neutralizing antibody.
【저자키워드】 COVID-19, neutralizing antibody, SARS-CoV-2, CoronaVac, anti-SARS-CoV-2 antibody, 【초록키워드】 neutralizing antibody, IgG, IgM, Efficacy, Vaccine, vaccination, Immunity, antibody, CoronaVac, prospective cohort study, anti-SARS-CoV-2, immune, SARS-CoV-2 vaccine, anti-SARS-CoV-2 antibodies, anti-SARS-CoV-2 antibody, SARS-CoV-2 variants, anti-Spike IgG, IgA, management, response, predictive values, antibody levels, booster dose, volunteers, Anti-spike, inactivated, immune protection, half-life, administration, dose, anti-RBD, regimen, Predictive, positive conversion, conversion rate, 95% CI, second dose, regimens, revaccination, fold, positive, decay, immune characteristics, FIVE, half-lives, evaluate, carried, remained, activate, subset, IgA level, much lower, half-live, the SARS-CoV-2, 【제목키워드】 Prospective, longitudinal, over, time, Day, Level, Increased, Point,